Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XH Histone deacetylase (HDAC) inhibitors
L01XH02 Romidepsin
D06637 Romidepsin (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Romidepsin
D06637 Romidepsin (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06637 Romidepsin (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03133 Histone deacetylase inhibitor
D06637 Romidepsin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D06637 Romidepsin
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Histone deacetylase
HDAC
D06637 Romidepsin (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06637
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06637
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06637
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06637